Prostate Cancer Clinical Trials in Philadelphia

Showing 301-320 of 339 trials

Communication and Intimacy-Enhancing Therapy for Men With Early Stage Prostate Cancer and Their Partners

NCT00503646

RATIONALE: Participating in a therapy program may enhance communication and intimacy between men with prostate cancer and their partners. PURPOSE: This randomized clinical trial is studying how well therapy enhances communication and intimacy for men with early stage prostate cancer and for their partners.

Prostate CancerPsychosocial Effects of Cancer and Its TreatmentSexual Dysfunction and Infertility+1 more

Memorial Sloan Kettering Cancer Center100 participantsStarted May 2007

New York, New York, United States • Philadelphia, Pennsylvania, United States

COMPLETEDNA< 1 mile

Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men

NCT01937585

The purpose of this study is to determine whether female partners of African American men can promote initiation of a discussion with a healthcare provider about prostate cancer screening when the partner is supported by a print message designed to provide relevant information and strategies for her to use in this effort.

Prostate Cancer

Fox Chase Cancer Center231 participantsStarted Aug 2010

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 2< 1 mile

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005848

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have progressive, metastatic prostate cancer that has not responded to hormone therapy.

Prostate Cancer

Fox Chase Cancer Center7 participantsStarted Apr 2000

Cleveland, Ohio, United States • Philadelphia, Pennsylvania, United States

Communication and Intimacy-Enhancing Therapy for Men With Early Stage Prostate Cancer and Their Partners

Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Prostate Cancer Trials in Other Cities

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Other Conditions in Philadelphia